EA201170940A1 - Лечение рака с использованием комбинации бендамустина и анти-cd20-антитела - Google Patents
Лечение рака с использованием комбинации бендамустина и анти-cd20-антителаInfo
- Publication number
- EA201170940A1 EA201170940A1 EA201170940A EA201170940A EA201170940A1 EA 201170940 A1 EA201170940 A1 EA 201170940A1 EA 201170940 A EA201170940 A EA 201170940A EA 201170940 A EA201170940 A EA 201170940A EA 201170940 A1 EA201170940 A1 EA 201170940A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- bendamustin
- cancer treatment
- antibody combination
- combination
- antibody
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 abstract 1
- 229960002707 bendamustine Drugs 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14521009P | 2009-01-16 | 2009-01-16 | |
| PCT/US2010/021123 WO2010083365A1 (en) | 2009-01-16 | 2010-01-15 | Treatment of a cancer using a combination of bendamustine and an anti-cd20 antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201170940A1 true EA201170940A1 (ru) | 2012-02-28 |
Family
ID=42340093
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201170940A EA201170940A1 (ru) | 2009-01-16 | 2010-01-15 | Лечение рака с использованием комбинации бендамустина и анти-cd20-антитела |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20110274697A1 (enExample) |
| EP (1) | EP2405937A4 (enExample) |
| JP (1) | JP2012515217A (enExample) |
| KR (1) | KR20110111303A (enExample) |
| CN (1) | CN102355907A (enExample) |
| AU (1) | AU2010204666A1 (enExample) |
| BR (1) | BRPI1006829A2 (enExample) |
| CA (1) | CA2749151A1 (enExample) |
| EA (1) | EA201170940A1 (enExample) |
| IL (1) | IL213794A0 (enExample) |
| MX (1) | MX2011007589A (enExample) |
| SG (1) | SG172792A1 (enExample) |
| WO (1) | WO2010083365A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI409079B (zh) * | 2009-08-14 | 2013-09-21 | Roche Glycart Ag | 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法 |
| CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP2857499A1 (en) | 2010-10-01 | 2015-04-08 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| CA2831613A1 (en) | 2011-03-31 | 2012-10-04 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| SG10201606785UA (en) * | 2011-08-16 | 2016-10-28 | Morphosys Ag | Combination therapy with an anti - cd19 antibody and a nitrogen mustard |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| FR2980110A1 (fr) * | 2011-09-20 | 2013-03-22 | Lfb Biotechnologies | Combinaison d'anticorps anti-cd20 et de bendamustine |
| PT3682905T (pt) | 2011-10-03 | 2022-04-07 | Modernatx Inc | Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações |
| ES2923757T3 (es) | 2011-12-16 | 2022-09-30 | Modernatx Inc | Composiciones de ARNm modificado |
| WO2013151664A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| PT2922554T (pt) | 2012-11-26 | 2022-06-28 | Modernatx Inc | Arn modificado nas porções terminais |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| KR20160067219A (ko) | 2013-10-03 | 2016-06-13 | 모더나 세라퓨틱스, 인코포레이티드 | 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드 |
| JP2019520419A (ja) * | 2016-07-13 | 2019-07-18 | 武田薬品工業株式会社 | 脾臓チロシンキナーゼ阻害剤と他の治療薬の併用 |
| EP3802622A4 (en) * | 2018-05-29 | 2021-08-18 | Wuxi Biologics Ireland Limited | NEW BISPECIFIC ANTI-CD3 / ANTI-CD20 ANTIBODY |
| CN110540593B (zh) * | 2018-05-29 | 2022-05-17 | 上海药明生物技术有限公司 | 新型的抗cd3/抗cd20双特异性抗体 |
| BR112021005104A2 (pt) | 2018-10-16 | 2021-06-08 | US Nano Food & Drug INC | formulação de injeção intratumoral |
| JP2023520975A (ja) | 2020-04-13 | 2023-05-23 | ユーエス・ナノ・フード・アンド・ドラッグ・インコーポレーテッド | 塩基性化学療法腫瘍内注射製剤 |
| CA3217391A1 (en) | 2020-07-27 | 2022-02-03 | Youwei ZHU | Formulation of novel bispecific anti-cd3/cd20 polypeptide complex |
| GB202218493D0 (en) * | 2022-12-08 | 2023-01-25 | Oncopeptides Ab | Novel therapeutic combinations |
| WO2024179545A1 (zh) * | 2023-03-01 | 2024-09-06 | 上海津曼特生物科技有限公司 | 包含cd20/cd47阻断双功能融合蛋白的联合用药物及其用途 |
| WO2024263798A1 (en) * | 2023-06-20 | 2024-12-26 | Burzynski Stanislaw R | Compositions comprising antineoplastons and methods of treating prostate cancer |
| WO2024263804A2 (en) * | 2023-06-20 | 2024-12-26 | Burzynski Stanislaw R | Compositions comprising antineoplastons and methods of treating kidney cancer |
| WO2024263801A2 (en) * | 2023-06-20 | 2024-12-26 | Burzynski Stanislaw R | Compositions comprising antineoplastons and methods of treating ovarian cancer |
| EP4731199A2 (en) * | 2023-06-21 | 2026-04-29 | Stanislaw R. Burzynski | Compositions comprising antineoplastons and methods of treating colorectal cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100944575B1 (ko) * | 2002-10-17 | 2010-02-25 | 젠맵 에이/에스 | Ｃｄ20에 대한 인간 모노클로날 항체 |
| US20070098718A1 (en) * | 2003-11-04 | 2007-05-03 | Chiron | Methods of therapy for b cell-related cancers |
| CA2627923C (en) * | 2005-11-10 | 2016-01-12 | Topotarget Uk Limited | Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer |
| US9382327B2 (en) * | 2006-10-10 | 2016-07-05 | Vaccinex, Inc. | Anti-CD20 antibodies and methods of use |
| EP2234641B1 (en) * | 2008-01-03 | 2015-08-19 | Genmab A/S | Monoclonal antibodies against cd32b |
-
2010
- 2010-01-15 EA EA201170940A patent/EA201170940A1/ru unknown
- 2010-01-15 BR BRPI1006829A patent/BRPI1006829A2/pt not_active IP Right Cessation
- 2010-01-15 MX MX2011007589A patent/MX2011007589A/es not_active Application Discontinuation
- 2010-01-15 US US13/144,335 patent/US20110274697A1/en not_active Abandoned
- 2010-01-15 EP EP10732123A patent/EP2405937A4/en not_active Withdrawn
- 2010-01-15 CN CN2010800123232A patent/CN102355907A/zh active Pending
- 2010-01-15 CA CA2749151A patent/CA2749151A1/en not_active Abandoned
- 2010-01-15 KR KR1020117018826A patent/KR20110111303A/ko not_active Withdrawn
- 2010-01-15 AU AU2010204666A patent/AU2010204666A1/en not_active Abandoned
- 2010-01-15 SG SG2011047107A patent/SG172792A1/en unknown
- 2010-01-15 WO PCT/US2010/021123 patent/WO2010083365A1/en not_active Ceased
- 2010-01-15 JP JP2011546347A patent/JP2012515217A/ja active Pending
-
2011
- 2011-06-27 IL IL213794A patent/IL213794A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN102355907A (zh) | 2012-02-15 |
| US20110274697A1 (en) | 2011-11-10 |
| CA2749151A1 (en) | 2010-07-22 |
| IL213794A0 (en) | 2011-07-31 |
| AU2010204666A1 (en) | 2011-07-21 |
| WO2010083365A1 (en) | 2010-07-22 |
| EP2405937A4 (en) | 2012-06-20 |
| SG172792A1 (en) | 2011-08-29 |
| KR20110111303A (ko) | 2011-10-10 |
| JP2012515217A (ja) | 2012-07-05 |
| BRPI1006829A2 (pt) | 2016-10-25 |
| MX2011007589A (es) | 2011-08-17 |
| EP2405937A1 (en) | 2012-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2011007589A (es) | Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20. | |
| CL2013000016A1 (es) | Compuestos derivados de imidazopiridina; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento del cancer. | |
| EA201690618A1 (ru) | Ингибиторы тирозинкиназы брутона | |
| EA201590855A1 (ru) | Соединения пирролопиримидина как ингибиторы киназ | |
| CL2013000018A1 (es) | Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros. | |
| CY1119616T1 (el) | Συζευγματα ανθρωπινου αντισωματος-φαρμακου κατα του ιστικου παραγοντα | |
| MX375752B (es) | Inhibidores de tirosina quinasa de bruton. | |
| CL2009001160A1 (es) | Compuestos derivados de heterociclos nitrogenados fusionados y su composicion farmaceutica. | |
| MX380273B (es) | Conjugados de farmacos anticuerpo (adcs) con inhibidores de ksp. | |
| CL2012000772A1 (es) | Compuestos derivados de hetorociclos carboxamidicos sustituidos, antagonista ar; composición farmacéutica que los comprende; y uso en el tratamiento del cáncer de próstata. | |
| EA033374B1 (ru) | Твердые фармацевтические композиции, содержащие энзалутамид, и способ лечения | |
| MX369106B (es) | Anticuerpo anti trop-2 humano que tiene actividad anti-tumoral in vivo. | |
| DOP2015000100A (es) | Inhibidores de la tirosina-quinasa de bruton | |
| PH12014501815A1 (en) | Purinone compounds as kinase inhibitors | |
| CL2015000829A1 (es) | Inhibidores de histona desmetilasas | |
| CL2015003395A1 (es) | Derivados pirazolopirrolidina y su uso en el tratamiento de la enfermedad | |
| UA107814C2 (uk) | Спірооксіндольні антагоністи мdм2 | |
| TN2012000335A1 (en) | Antibody formulation and therapeutic regimens | |
| EA201390682A1 (ru) | Спирооксиндольные антагонисты mdm2 | |
| EA201391719A1 (ru) | Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний | |
| JOP20130236B1 (ar) | تركيبات صيدلانية تشتمل على مثبط b-raf ومثبط egfr ومثبط اختياري لــpi3k alpha | |
| MX382476B (es) | Dispersiones solidas de bendamustina e infusion continua. | |
| BR112013033544A2 (pt) | dosagem e administração de anticorpos anti-erbb3 em combinação com paclitaxel para tratamento de cânceres ginecológicos | |
| CL2011000168A1 (es) | Compuestos derivados de narciclasina y pancratistatina; procedimiento de preparación; composición farmacéutica; combinación farmacéutica; y su uso para el tratamiento del cáncer. | |
| CL2014001323A1 (es) | Compuestos derivados de 3-fenil-isoquinolin-1(2h)-ona, inhibidores de parp-1; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer. |